Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
WALB,
SOURCE Novartis - Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years1,2 …